The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction by Michalski, Błażej et al.
Address for correspondence: Błażej Michalski, MD, Department of Cardiology, Medical University of Lodz, Bieganski  
Hospital, ul. Kniaziewcza 1/5, 91–347 Łódź, Poland, tel: +48 501681795, fax: +48 422516015, e-mail: bwmichalski@op.pl
Received: 25.04.2016 Accepted: 06.08.2016
The differences in the relationship between  
diastolic dysfunction, selected biomarkers and  
collagen turn-over in heart failure patients  
with preserved and reduced ejection fraction
Błażej Michalski1, Przemysław Trzciński1, Karolina Kupczyńska1, Dawid Miśkowiec1, 
Łukasz Pęczek2, Barbara Nawrot2, Piotr Lipiec1, Jarosław D. Kasprzak1
1Department of Cardiology, Medical University of Lodz, Poland 
2Centre of Molecular and Macromolecular Studies of the Polish Academy of Sciences,  
Department of Bioorganic Chemistry, Lodz, Poland
Abstract
Background: The aim of the study was to assess the correlation of the selected biomarkers and col-
lagen turn-over indices with advanced echocardiographic parameters among patients with preserved 
and reduced ejection fraction (EF).
Methods: We included 62 patients with the symptomatic heart failure. The patients were divided in 
to two groups according to the evaluated ejection fraction (EF — Simpson method): heart failure with 
reduced ejection fraction (HFrEF) group — 30 patients with low EF — 35–50% (16 male, mean age 
54.9 ± 12.6), heart failure with preserved ejection fraction (HFpEF) group — 32 patients with EF 
> 50% (16 male, mean age 62.3 ± 7.6). Clinical evaluation included 6-min walk test, biochemistry, 
procollagen type I N-terminal propeptide (PINP), procollagen type III N-terminal propetide (PIIINP), 
matrix metaloproteinase-2 (MMP2), ghrelin, and galectin-3 levels measurements. Echocardiographic 
examination was performed with analysis of diastolic function and global longitudinal strain (GLS).
Results: The GLS in the HFrEF group was significantly lower than in the HFpEF group at the baseline  
(GLS: 9.56 vs. 16.03, p < 0.01). There was a strong negative correlation of the PIIINP and GLS in 
HFrEF group (r = –0.74, p = 0.005), but only a moderate negative correlation in HFpEF (r = –0.55, 
p = 0.02). In the HFrEF group, there was a moderate negative correlation between the baseline level 
of galectin-3 and GLS (r = –0.59, p = 0.03). The correlation of ghrelin and tissue inhibitor of matrix 
metalloproteinase-1 with EF in the HFrEF group was moderate and statistically significant (r = 0.62, 
p = 0.02 and r = –0.63, p = 0.02, respectively).
Conclusions: Procollagen type III peptide has a strong negative correlation with left ventricular GLS. 
Galectin-3 relationship with strain may indicate novel pathophysiological pathways and requires further 
investigation. (Cardiol J 2017; 24, 1: 35–42)
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Introduction
More than 50% of patients with heart failure 
symptoms present with normal ejection fraction 
(HFpEF) [1]. Myocardial fibrosis and diastolic dys-
function are considered landmarks of the developed 
HFpEF. The major risk factors are age, diabetes, 
and hypertension. In clinical practice, echocardiog-
raphy is the first-line diagnostic method, however 
accurate diagnosis of HFpEF remains a challenge, 
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as mitral flow Doppler alone has 40–70% specificity 
in reliable detection of diastolic dysfunction [2, 3]. 
Tissue Doppler imaging (TDI), including the left 
ventricular (LV) filling index and transmitral flow 
velocity to annular velocity ratio (E/E’), are useful 
for the determination of LV filling pressure [4]. The 
LV filling index E/E’ is a clinically accepted marker 
but has limitations in characterization of diastolic 
dysfunction [5]. Strain and strain rate by speckle 
tracking are angle-independent methods validated 
for the evaluation of cardiac function [6]. Longitudi-
nal myocardial shortening assessment contributes 
to the overall assessment of myocardial function 
and diastolic dysfunction, although it is not superior 
to already established TDI analysis including E/E’ 
in patients with only mild degree of disease [7].
Myocardial histological changes, including ex-
tracellular collagen deposition, strongly influence 
LV systolic and diastolic properties. In patients 
with hypertension, accumulation of collagen I and III 
was increased. Animal studies of LV hypertrophy 
indicate that despite the preserved ejection frac-
tion (EF), the amount of collagen accompanied 
by abnormal diastolic stiffness is present [8]. In 
patients with ischemic heart disease, hormonal 
and immune activation affects the progression of 
LV dysfunction and heart failure (HF) [9]. Elevated 
serum levels of collagen III reflect myocardial 
remodeling, which is associated with significant 
LV dilatation and persistently depressed LVEF 
[10]. In this study, we investigated the correlation 
of the collagen turnover biomarkers and selected 
adipokines with markers of myocardial function 
evaluated by echocardiography in patients with 
heart failure with reduced or preserved ejection 
fraction (HFrEF; HFpEF). We chose adiponectin, 
leptin, galectin-3, and ghrelin due to recently pub-
lished data which suggest their important role in di-
astolic dysfunction [11–13]. Leptin is an adipokine 
which attenuates the LV hypertrophy and improves 
diastolic function of the heart [14]. Adiponectin may 
play an important role in protection against cardiac 
remodeling by attenuating myocardial hypertrophy 
[15]. Galectin receptors have been detected in 
macrophages in dysfunctional hearts and galectin-3 
was suggested to correlate with echocardiographic 
indices of diastolic function [16]. Ghrelin is a strong 
stimulant for the release of growth hormone and 
can reduce peripheral vascular resistance, thus car-
diac index and stroke volume index can potentially 
improve ventricular remodeling [17]. Apelin is an 
endogenous peptide with many isoforms of which 
apelin-13 is the most active in the heart. Apelin-13 
induces vasodilation which leads to a reduction 
in mean filling pressure, resulting in a decrease 
of preload and afterload [18]. The purpose of this 
study was to establish the relationship of selected 
adipokines and collagen turnover products with di-
astolic dysfunction among patients with preserved 
and reduced ejection fraction.
Methods
We enrolled 62 patients from our outpatient 
clinic with HF symptoms. They were divided 
into two groups according to the EF: group I — 
HFrEFF with EF < 50% and EF > 35%, group II 
— patients with HFpEF and EF > 50%. All 
patients had exercise dyspnea or exercise intoler-
ance, captured by abnormal 6-min walk test and 
elevated N-terminal-pro-B type natriuretic peptide 
(NT-proBNP) plasma levels. Patients with HFrEF 
had a history of ST elevation myocardial infarction 
treated with primary coronary angioplasty of the 
single vessel at least 6 months but no more than 
24 months before the inclusion into the study. Patients 
with HFpEF were included according to the recent 
European Society of Cardiology guidelines and 
they presented symptoms of the HF, LVEF ≥ 50%, 
elevated NT-proBNP, and enlargement of the left 
atrium (LAE) or LV hypertrophy [19]. Patients with 
acute or decompensated HF were excluded. Atrial 
fibrillation, significant valvular or coronary artery 
disease, as obtained by angiography or computed 
tomography of the coronary arteries, and lung 
diseases, as obtained by X-ray and functional test, 
resulted in patient exclusion. Patients with tissue 
fibrosis disease, such as chronic liver disease, 
pulmonary fibrosis, or rheumatoid arthritis were 
excluded, because these conditions are associated 
with increased collagen turnover biomarkers. At 
the baseline, the laboratory evaluation included 
blood level of C-reactive protein, NT-proBNP, 
adiponectin, ghrelin, leptin, fasting glucose, lipid 
profile, 6-min walk test and echocardiographic ex-
amination with the TDI and strain analysis. Each 
patient included into the study had signed the 
informed consent. The study was approved by the 
local Ethics Committee.
Echocardiography
All patients underwent echocardiographic 
examination performed on VIVID 9 (2.5 MHz 
probe, GE Ultrasound). The standard parasternal 
and apical views to evaluate the heart chamber’s 
dimensions, valve function, EF and diastolic func-
tion (E/A) were obtained [20]. For speckle tracking, 
according to the technical requirements, a high 
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temporal resolution of the recorded cine-loop 2-di-
mensional images (in grayscale) was set to achieve 
at least 60 frames per second (FPS) or more. The 
speckle tracking echocardiography analysis included 
the manual contouring of the LV endocardium and the 
approval of the proper level of the imaging quality 
of the analyzed area. The LV strain was calculated 
offline using a dedicated workstation with software 
enabling speckle tracking (EchoPac version 12.1.0, 
GE Healthcare). The average value of peak systolic 
longitudinal strain and peak systolic strain rate from 
all three apical views was then calculated as global 
strain (SISYS) and global strain rate (SRSYS), respective-
ly [4]. Similarly, peak global strain rate during early 
(SRE) and late (SRL) diastole and during isovolumetric 
relaxation (SRIVR) was determined. Diastolic indices 
E/SRE and E/SRIVR were calculated [7]. During TDI, 
a 1.5 mm sample volume was placed at the leaflet 
origin of the mitral annulus. Early (E’) diastolic peak 
velocities of LV longitudinal fibers were measured 
at the lateral and septal mitral annulus from apical 
4 chamber view with 1.5 mm sample volume of the 
pulsed wave tissue Doppler.
Laboratory tests
Blood samples for specified biomarkers were 
collected on the day of echocardiographic examina-
tion at 8:00 a.m. after at least 14 h of fasting. The 
citrated plasma and serum were stored at –70°C 
until assaying. All markers were measured by an 
enzyme-linked immunosorbent assay (ELISA) — 
leptin and adiponectin (BioVendor — Laboratorni 
medicina a.s., Brno, Czech Republic), procollagen I 
carboxyterminal propeptide (PICP), matrix metal-
lopeptidase 2 (MMP2), tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1), procollagen type I 
N-terminal propeptide (PINP), galectin-3 (GAL-3), 
collagen type I-telopeptide (CTXI), apelin 13, ghre-
lin, and procollagen type III N-terminal propeptide 
(PIIINP) (Cloud-Clone Corp., Houston, TX, USA) 
in the laboratory of the Department of Bioorganic 
Chemistry of Center of Molecular and Macromo-
lecular Studies of the Polish Academy of Science 
in Lodz, Poland. Serum concentrations of sodium, 
potassium, creatinine, creatine kinase isoenzyme 
MB mass (CK-MB), troponin C, and lipids were 
assessed in all patients.
Statistical analysis
The analyses were performed using the Statis-
tica 8.0 (StatSoft Polska, Krakow, Poland) software. 
The normality of the distribution was tested with 
the Shapiro-Wilk’s test. The analysis of variance 
was performed using Levene’s test and the Brown-
Forsythe test. Student’s t-test for independent vari-
ables and the Mann-Whitney U pairwise comparison 
for independent variables were used as appropriate. 
The correlation coefficients were calculated accord-
ing to Spearman’s or Pearson’s method. Values of 
p < 0.05 were considered statistically significant. All 
presented data are expressed as means and standard 
deviations or medians and quartiles.
Results
Patient characteristics
Baseline characteristics of the included pa-
tients are summarized in Table 1. The average 
age in the HFrEF group (35% < EF < 50%) was 
54.9 ± 12.6 years and in the HFpEF group (EF 
> 50%) it was 62.3 ± 7.6 years. Patients with 
HFpEF showed a significantly lower level of NT-
-proBNP (211.86 ± 68.5 pg/mL vs. 738.2 ± 1,105.4 
pg/mL, p < 0.05). Moreover, diabetes mellitus was 
more frequent among patients with HFpEF. In ad-
dition, in HFrEF and HFpEF groups, frequency of 
therapy with an angiotensin-converting enzyme 
inhibitor or angiotensin-receptor blocker (90% vs. 
94%), diuretic use (60% vs. 31%) and beta-blockers 
(97% vs. 94%) was high.
Echocardiography
Heart volumes, as well as flow and tissue 
Doppler measurements are listed in Table 2. LVEF 
was lower in the HFrEF than in the HFpEF group 
(38.6% vs. 59.5%, p < 0.05); also global longitu-
dinal strain at aortic valve closure (GLSAVC) was 
lower in patients with HFrEF (–9.56 vs. –16.03, 
p < 0.05). In patients with HFrEF the LV end dias-
tolic volume was larger than in HFpEF (122.3 vs. 
93 ± 22.2, p < 0.05) and the LV mass index was 
increased. Patients from HFrEF had the increased 
E’/A E/E’ and decreased SRIVR, SRE, SRL.
The levels of biomarkers
Ghrelin and leptin concentrations were statis-
tically significantly lower in the group with HFrEF, 
in contrast to the elevated level of PICP (Table 3). 
The correlation of ghrelin and TIMP1 with EF in the 
HFrEF group was moderate and statistically signifi-
cant (r = 0.62, p = 0.02 and r = –0.63, p = 0.02, 
respectively). In the HFpEF group, there was 
a moderate correlation of EF and PIIINP (r = –0.56, 
p = 0.01). In the HFpEF group, there was statisti-
cally significant correlation of the PINP and PICP 
with LV end systolic volume (r = –0.4, p = 0.02 
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and r = –0.38, p = 0.28, respectively). However, 
such statistically significant correlation in the 
group with HFpEF was only observed for LV end 
diastolic volume and PIIINP (r = –0.57, p = 0.04).
There was a strong negative correlation of the 
PIIINP and GLSAVC in the HFrEF group (r = –0.74, 
p = 0.005), yet only a moderate negative correla-
tion in HFpEF group (r = –0.55, p = 0.02). In the 
Table 2. Baseline echocardiographic characteristics of group 1 and group 2.
Echocardiographic  
characteristics
Group 1 — HFrEF (n = 30) 
(35% < EF < 50%)
Group 2 — HFpEF (n = 32)  
(EF > 50%)
P
EDV [mL] 125 ± 40.4 93 ± 22.2 0.0008*
ESV [mL] 78 ± 30.2 32 ± 9.5 < 0.0001*
LVMI [g/m2] 173.0 ± 36.4 137.1 ± 21.4 0.0004
LVEF [%] 38.3 ± 8.1 59.9 ± 2.9 < 0.0001*
E’ [cm/s] 7.89 ± 1.8 6.3 ± 0.9 0.03
E/A ratio 1.1 ± 0.56 1.213 ± 0.42 0.041
E/E’ ratio 9.4 ± 6.15 1532 ± .4.613 0.007*
GLSAVC 9.56 ± 2.3 16.03 ± 2.9 < 0.0001
GLSMax 10.68 ± 2.99 16.12 ± 6.4 < 0.0001
SRSYS 0.56 ± 0.16 0.8 ± 0.22 < 0.0001
SRIVR 0.11 ± 0.12 0.16 ± 0.22 0.63*
*U-Mann-Whitney, all data expressed as medians; HFpEF — heart failure with preserved ejection fraction; HFrEF — heart failure with reduced 
ejection fraction; EDV — end diastolic volume; ESV — end systolic volume; LVMI — left ventricular mass index; LVEF — left ventricular ejec-
tion fraction; GLSAVC — global longitudinal strain at aortic valve closure; GLSMax — maximal global longitudinal strain; SRSYS — global systolic 
strain rate; SRIVR — global strain rate during isovolumetric relaxation
Table 1. Baseline characteristics of group 1 and group 2.
Clinical characteristic Group 1 — HFrEF (n = 30) Group 2 — HFpEF (n = 32) P
Age 54.9 ± 12.6 62.3 ± 7.6 0.005
Female: 14 (47%) 16 (47%) 0.76
NYHA class 2.4 ± 0.6 2.6 ± 0.3 0.11
Medical history:
Myocardial infarction 0 (0%) 0 (0%) > 0.05
Hypertension 29 (97%) 31 (97%) 0.96
Diabetes mellitus 9 (30%) 10 (31%) 0.91
Systolic BP [mm Hg] 134 ± 11.9 (121–143) 138 ± 11.8 (121–147) 0.55
Diastolic BP [mm Hg] 79 ± 9.5 (70–83) 85 ± 8.2 (76–89) 0.42
Body mass index 29.3 ± 4.8 27.9 ± 3.7 0.28
6 min walk test [m] 341.2 ± 48.7 349.32 ± 62.1 0.49
NT-proBNP [pg/mL] 738.2 ± 1105.4 211.86 ± 68.5 0.01
Medication:
Beta-blocker 29 (97%) 30 (94%) 0.89
ACEI/ARB 29 (97%) 31 (97%) 0.95
Spironolactone 27 (90%) 30 (94%) 0.58
Thiazides 18 (60%) 10 (31%) 0.02
Oral diabetic drugs 9 (30%) 10 (31%) 0.91
Calcium channel blocker 0 (0%) 4 (13%) 0.04
Digoxin 7 (23%) 0 (0%) 0.01
Statins 19 (63%) 21 (66%) 0.65
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; HFpEF — heart failure with  
preserved ejection fraction; HFrEF — heart failure with reduced ejection fraction; NYHA — New York Heart Association; NT-proBNP —  
N-terminal-pro-B type natriuretic peptide
38 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 1
HFrEF group, there was a moderate negative cor-
relation between the levels of GAL-3 and GLSAVC 
(r = –0.59, p = 0.03).
In the group with HFrEF, there was a statisti-
cally significant correlation of the PICP with the 
E/A values (r = 0.62, p = 0.02) and GAL-3 with 
E/E’ (r = 0.64, p = 0.03) (Table 4). However, in 
this group, we can observe an inverse correlation 
of apelin and ghrelin with the E/E’ (r = –0.56, 
p = 0.03 and r =–0.72, p = 0.01, respectively) 
(Table 4). According to the flow Doppler measure-
ments in patients with HFpEF, we observed the 
correlation of PIIINP with E/A and adiponectin 
with E (r = 0.46, p = 0.03 and r = 0.64 p = 0.02, 
Table 3. Baseline characteristics of biomarkers in group 1 and group 2. 
Biomarkers Group 1 — HFrEF (n = 30) 
(35% < EF < 50%)
Group 2 — HFpEF (n = 32)  
(EF > 50%)
P
Apelin-13 [ng/mL] 2.2 ± 1.9 1.28 ± 1.41 0.1
Adiponectin [µg/mL] 8.88 ± 3.95 8.83 ± 3.38 0.69
Ghrelin [pg/mL] 2847 ± 2776 1464 ± 1212 0.039
Galectin-3 [ng/mL] 13.53 ± 8.45 10.71 ± 4.21 0.51
Leptin [ng/mL] 18.23 ± 14.1 26.44 ± 14.29 0.045
CTXI [pg/mL] 239 ± 125.2 232 ± 94.4 0.88
PINP [ng/mL] 30.77 ± 27.4 22.21 ± 14.1 0.63
PICP [ng/mL] 154 ± 112.38 99.21 ± 45.3 0.01
MMP2 [ng/mL] 15.67 ± 6.2 15.88 ± 8.6 0.35
PIIINP [ng/mL] 14.39 ± 8.41 13.22 ± 6.17 0.68
TIMPI [ng/mL] 227 ± 131 216 ± 93 0.81
U-Mann-Whitney all data expressed as median values; HFpEF — heart failure with preserved ejection fraction; HFrEF — heart failure with 
reduced ejection fraction; CTXI — collagen type I-telopeptide; PICP — procollagen I carboxyterminal propeptide; PINP — procollagen type I 
N-terminal propeptide; PIIINP — procollagen type III N-terminal propeptide; MMP-2 — matrix metallopeptidase 2; TIMP-1 — tissue inhibitor of 
matrix metalloproteinase-1
Table 4. The correlation of biomarkers with diastolic parameters in patients with HFrEF and HFpEF.
Biomarkers HFrEF (n = 30) HFpEF (n = 35)
E/A E/E’ E A E/A E/E’ E A
Apelin NS r = –0.56 
p = 0.03
NS NS NS NS NS NS
Adiponectin NS NS NS NS NS r = 0.45 
p = 0.01
r = 0.64 
p = 0.02
NS
Galectin 3 NS r = 0.64 
p = 0.03
r = 0.69 
p = 0.04
NS NS NS NS NS
Ghrelin NS r = –0.72 
p = 0.01
NS NS NS NS NS NS
Leptin NS NS NS NS NS NS NS NS
CTXI NS NS NS NS NS NS NS NS
PICP r = 0.62 
p = 0.02
NS NS r = –0.61 
p = 0.01
NS NS NS NS
PINP NS NS NS NS NS NS NS NS
PIIINP NS NS NS NS r = –0.46 
p = 0.03
NS NS NS
MMP-2 NS NS NS NS NS r = 0.45 
p = 0.03
r = 0.52 
p = 0.03
NS
HFpEF — heart failure with preserved ejection fraction; HFrEF — heart failure with reduced ejection fraction; CTXI — collagen type I-telopep-
tide; PICP — procollagen I carboxyterminal propeptide; PINP — procollagen type I N-terminal propeptide; PIIINP — procollagen type III  
N-terminal propeptide; MMP-2 — matrix metallopeptidase 2
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respectively). The TDI data in the HFpEF group 
showed the correlation of adiponectin and MMP-2 
with E/E’ (r = 0.45, p = 0.013 and r = 0.45, 
p= 0.03, respectively).
Discussion
The key finding of our study was an evidence 
of a relationship between the different levels of 
selected biomarkers and echocardiographic pa-
rameters among patients with HFpEF or HFrEF. 
The early diastolic velocity of the mitral valve 
annulus (E’) reflects the rate of myocardial relaxa-
tion and the E/E’ ratio is more sensitive than the 
E/A ratio for identifying LV diastolic dysfunction 
[21]. Unlike other Doppler parameters of diastolic 
function, E’ velocity appears to be relatively inde-
pendent from preload, especially when the rate of 
myocardial relaxation is decreased [21]. In addition, 
the ratio of early transmitral flow velocity (E) to 
early diastolic septal mitral annulus velocity (E/E’) 
 has been recently shown to be the most accurate non-
invasive predictor of elevated LV filling pressure [21].
The levels of apelin and galectin were higher in 
the HFrEF group. It was previously confirmed on 
an animal model that the level of apelin is higher in 
HF and it leads to an increase in contractility of the 
heart muscle without pressure overload [22]. The 
increased level of PCIP and PINP among patients 
with HFrEF suggests a correlation with myocardial 
fibrosis and diastolic dysfunction. Increased colla-
gen level in this group indicates an early remodeling 
process that causes an increase in the ventricular 
stiffness resulting in diastolic dysfunction. There 
was also a strong inverse correlation in the HFrEF 
group of ghrelin with apelin and positive of GAL-3 
with  E/E’. The inverse correlation of apelin with 
E/E’ and its protective activity was also confirmed 
on a murine animal model where administration of 
apelin resulted in reduced LV preload and afterload, 
and increased contractile reserve without evidence 
of hypertrophy [22]. Additionally, apelin prevents 
tissue growth factor-beta from inducing both, the 
expression of myofibroblast marker alpha-smooth 
muscle actin and collagen production [23].
Adiponectin also plays an important role in 
the LV chamber remodeling and changes in the 
cardiac structure [24]. It increases the extracellular 
matrix remodeling by enhancing fibroblast migra-
tion and increasing the level of collagen III and 
total collagen [25]. In our study, only in the group 
with HFpEF there was a moderate correlation of 
adiponectin with E values (r = 0.64, p = 0.02). It 
has been previously shown in an animal model that 
expression of the myocardial adiponectin gene may 
be decreased in the presence of pressure overload, 
whereas the serum level of adiponectin may be 
increased [25].
In patients with HFpEF the level of ghrelin was 
significantly lower than in patients with HFrEF. The 
increased level of ghrelin among the HFrEF patients 
correlates with previous literature reports [26, 27]. 
However, there is no data available for the charac-
teristic levels of ghrelin among patients with HF-
pEF. In the study by Tarek et al. [28], patients with 
HFpEF had elevated levels of leptin, which opposes 
ghrelin and may be the reason for the mild elevation 
of ghrelin. Moreover, among patients with HFrEF, 
we have observed an inverse correlation between 
ghrelin and E/E’ which is interesting with respect 
to ghrelin’s ability to decrease the production of 
collagen by fibroblasts [29]. This may be caused 
by the fact that relaxation induced by ghrelin was 
decreased by inhibition of prostaglandins release 
and exacerbated by nitric oxide synthase inhibition 
[30]. Furthermore, the higher level of ghrelin in 
patients with HFrEF may have a cardioprotective 
effect because ghrelin attenuates pressure overload 
induced by cardiac hypertrophy via a cholinergic 
anti-inflammatory pathway and decreases deposition 
of collagen in the heart muscle [31, 32].
The correlation of GAL-3 was positive with 
E/E’ and E value among patients with HFrEF, how-
ever such results were not observed for HFpEF 
patients. In patients with HFrEF we also observed 
the correlation of GAL-3 and GLSAVC.
Correlations of GAL-3 with fibrosis and PIIINP 
with impaired filling pressure of the LV were 
obtained with the use of cardiovascular magnetic 
resonance (CMR) by Lepojarvi et al. [33]. More-
over, in the study by Lin et al. [34], it was confirmed 
that the level of galectin correlates with the turn-
over of biomarkers of extracellular matrix among 
patients with HFrEF.
In a very big study on a cohort of 600 patients, 
the level of galectin was shown to be similar in 
patients with HFpEF and HFrEF, although the 
increase of galectin levels leads to higher risk of 
composite end-point (all-cause mortality and HF 
hospitalization) in patients with HFpEF [35]. How-
ever, recent studies have shown that GAL-3 is not 
a critical modulator of cardiac fibrosis but may delay 
the hypertrophic response and further studies are 
needed to clearly establish its role [36]. Interest-
ingly, in patients with HFpEF, there was a statisti-
cally significant correlation between adiponectin 
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and MMP-2 with the E/E’ and an inverse correla-
tion of PIIINP with E/A. Frantz et al. [37] reported 
similarly elevated TIMP-1 levels in hospitalized 
HFpEF and HFrEF patients. Alterations in MMP, 
especially in MMP-2, were found to be significant 
indicators of greater degrees of asymptomatic LV 
diastolic dysfunction in patients with HFpEF [38]. 
The present findings show that myocardial collagen 
type I synthesis is linked to increased LV stiffening 
(an inverse correlation with A: r = –0.61, p = 0.01 
and positive with E/A: r = 0.62, p = 0.02) but only 
in HFrEF. This corresponds with the findings by 
Löfsjögård et al. [39] that biomarkers of collagen 
type I synthesis and degradation are independently 
related to LV size and diastolic function in the sys-
tolic HF. Furthermore, in our study, we observed 
an irreversible correlation of PIIINP with E/A (r = 
–0.46, p = 0.03) and with GLSAVC in HFpEF group. In 
the recently published study PIIINP was confirmed 
to be the first early biomarker for the HF develop-
ment in patients with hypertension and normal 
resting echocardiography [40]. Similar results were 
confirmed with multi-biomarker approach and the 
evaluation of the diastolic function by CMR [33].
Among patients with HFrEF, the collagen 
turnover was higher than in the group with HFpEF 
and this may also be a predictor of multiple cardiac 
events, especially in the elderly [41]. Although the 
GLSAVC values were lower in the group with HFrEF, 
we have observed the negative correlation with 
PIIINP levels in both groups.
Conclusions
These results provide further support for the 
hypothesis that fibrosis is an important contributor 
towards the development of HF and serum mark-
ers of collagen turnover and adipokines play an 
important role in diastolic dysfunction. In patients 
with HFrEF and HFpEF, the level of apelin, ghre-
lin, leptin, and PICP varies significantly. There is 
a moderate correlation of selected adipokines and 
collagen turnover products with the diastolic dys-
function in patients with HFrEF and HFpEF. The 
protective effect of apelin on diastolic dysfunction 
was observed only in the HFrEF group, however, 
the negative effect for MMP-2 and adiponectin 
was present in the HFpEF group. Procollagen 
type III peptide has a strong negative correlation 
with LV global longitudinal strain. Galectin-3 and 
ghrelin relationship with strain may indicate novel 
pathophysiological pathways and require further 
investigation.
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